J. Exp. Med., Volume 188, Number 5, September 7, 1998 997-1001

TRANCE Is Necessary and Sufficient for Osteoblast-mediated Activation of Bone Resorption in Osteoclasts

By Karen Fuller,^* Brian Wong,^§ Simon Fox,^* Yongwon Choi,^§ and Tim J. Chambers^*

From the ^* St. George's Hospital Medical School, London SW17 ORE, United Kingdom; and the  Howard Hughes Medical Institute, ^§ The Rockefeller University, New York 10021

TRANCE (tumor necrosis factor-related activation-induced cytokine) is a recently described member of the tumor necrosis factor superfamily that stimulates dendritic cell survival and has also been found to induce osteoclastic differentiation from hemopoietic precursors. However, its effects on mature osteoclasts have not been defined. It has long been recognized that stimulation of osteoclasts by agents such as parathyroid hormone (PTH) occurs through a hormonal interaction with osteoblastic cells, which are thereby induced to activate osteoclasts. To determine whether TRANCE accounts for this activity, we tested its effects on mature osteoclasts. TRANCE rapidly induced a dramatic change in osteoclast motility and spreading and inhibited apoptosis. In populations of osteoclasts that were unresponsive to PTH, TRANCE caused activation of bone resorption equivalent to that induced by PTH in the presence of osteoblastic cells. Moreover, osteoblast-mediated stimulation of bone resorption was abrogated by soluble TRANCE receptor and by the soluble decoy receptor osteoprotegerin (OPG), and stimulation of isolated osteoclasts by TRANCE was neutralized by OPG. Thus, TRANCE expression by osteoblasts appears to be both necessary and sufficient for hormone-mediated activation of mature osteoclasts, and TRANCE-R is likely to be a receptor for signal transduction for activation of the osteoclast and its survival.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Takahashi, T., Uehara, H., Bando, Y., Izumi, K. (2008). Soluble EP2 neutralizes prostaglandin E2-induced cell signaling and inhibits osteolytic tumor growth. Molecular Cancer Therapeutics 7: 2807-2816 [Abstract] [Full Text]  
• Lorenzo, J., Horowitz, M., Choi, Y. (2008). Osteoimmunology: Interactions of the Bone and Immune System. Endocr. Rev. 29: 403-440 [Abstract] [Full Text]  
• Bone, H. G., Bolognese, M. A., Yuen, C. K., Kendler, D. L., Wang, H., Liu, Y., San Martin, J. (2008). Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women. J. Clin. Endocrinol. Metab. 93: 2149-2157 [Abstract] [Full Text]  
• Kearns, A. E., Khosla, S., Kostenuik, P. J. (2008). Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease. Endocr. Rev. 29: 155-192 [Abstract] [Full Text]  
• Vega, D., Maalouf, N. M., Sakhaee, K. (2007). The Role of Receptor Activator of Nuclear Factor-{kappa}B (RANK)/RANK Ligand/Osteoprotegerin: Clinical Implications. J. Clin. Endocrinol. Metab. 92: 4514-4521 [Abstract] [Full Text]  
• Lipton, A., Steger, G. G., Figueroa, J., Alvarado, C., Solal-Celigny, P., Body, J.-J., de Boer, R., Berardi, R., Gascon, P., Tonkin, K. S., Coleman, R., Paterson, A. H.G., Peterson, M. C., Fan, M., Kinsey, A., Jun, S. (2007). Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases. JCO 25: 4431-4437 [Abstract] [Full Text]  
• Pearse, R. N. (2006). Wnt antagonism in multiple myeloma: a potential cause of uncoupled bone remodeling.. Clin. Cancer Res. 12: 6274s-6278s [Abstract] [Full Text]  
• Yeh, H. S., Berenson, J. R. (2006). Treatment for myeloma bone disease.. Clin. Cancer Res. 12: 6279s-6284s [Abstract] [Full Text]  
• Ma, G.-F., Liljestrom, M., Ainola, M., Chen, T., Tiainen, V.-M., Lappalainen, R., Konttinen, Y. T., Salo, J. (2006). Expression of ADAM9 (meltrin-{gamma}) around aseptically loosened total hip replacement implants. Rheumatology (Oxford) 45: 808-814 [Abstract] [Full Text]  
• Torikai, E., Kageyama, Y., Takahashi, M., Suzuki, M., Ichikawa, T., Nagafusa, T., Nagano, A. (2006). The effect of infliximab on bone metabolism markers in patients with rheumatoid arthritis. Rheumatology (Oxford) 45: 761-764 [Abstract] [Full Text]  
• Dewar, A. L., Farrugia, A. N., Condina, M. R., Bik To, L., Hughes, T. P., Vernon-Roberts, B., Zannettino, A. C. W. (2006). Imatinib as a potential antiresorptive therapy for bone disease. Blood 107: 4334-4337 [Abstract] [Full Text]  
• Yoshida, H., Okamoto, K., Iwamoto, T., Sakai, E., Kanaoka, K., Hu, J.-P., Shibata, M., Hotokezaka, H., Nishishita, K., Mizuno, A., Kato, Y. (2006). Pepstatin A, an Aspartic Proteinase Inhibitor, Suppresses RANKL-Induced Osteoclast Differentiation.. J Biochem 139: 583-590 [Abstract] [Full Text]  
• Liu, W., Wang, S., Wei, S., Sun, L., Feng, X. (2005). Receptor Activator of NF-{kappa}B (RANK) Cytoplasmic Motif, 369PFQEP373, Plays a Predominant Role in Osteoclast Survival in Part by Activating Akt/PKB and Its Downstream Effector AFX/FOXO4. J. Biol. Chem. 280: 43064-43072 [Abstract] [Full Text]  
• Schneeweis, L. A., Willard, D., Milla, M. E. (2005). Functional Dissection of Osteoprotegerin and Its Interaction with Receptor Activator of NF-{kappa}B Ligand. J. Biol. Chem. 280: 41155-41164 [Abstract] [Full Text]  
• Frick, K. K., LaPlante, K., Bushinsky, D. A. (2005). RANK ligand and TNF-{alpha} mediate acid-induced bone calcium efflux in vitro. Am. J. Physiol. Renal Physiol. 289: F1005-F1011 [Abstract] [Full Text]  
• Yamazaki, H., Sasaki, T. (2005). Effects of osteoprotegerin administration on osteoclast differentiation and trabecular bone structure in osteoprotegerin-deficient mice. J Electron Microsc (Tokyo) 54: 467-477 [Abstract] [Full Text]  
• Kim, N., Kadono, Y., Takami, M., Lee, J., Lee, S.-H., Okada, F., Kim, J. H., Kobayashi, T., Odgren, P. R., Nakano, H., Yeh, W.-C., Lee, S.-K., Lorenzo, J. A., Choi, Y. (2005). Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J. Exp. Med. 202: 589-595 [Abstract] [Full Text]  
• Mangashetti, L. S., Khapli, S. M., Wani, M. R. (2005). IL-4 Inhibits Bone-Resorbing Activity of Mature Osteoclasts by Affecting NF-{kappa}B and Ca2+ Signaling. J. Immunol. 175: 917-925 [Abstract] [Full Text]  
• Min, J.-K., Kim, Y.-M., Kim, S. W., Kwon, M.-C., Kong, Y.-Y., Hwang, I. K., Won, M. H., Rho, J., Kwon, Y.-G. (2005). TNF-Related Activation-Induced Cytokine Enhances Leukocyte Adhesiveness: Induction of ICAM-1 and VCAM-1 via TNF Receptor-Associated Factor and Protein Kinase C-Dependent NF-{kappa}B Activation in Endothelial Cells. J. Immunol. 175: 531-540 [Abstract] [Full Text]  
• Vidal, K., Serrant, P., Schlosser, B., van den Broek, P., Lorget, F., Donnet-Hughes, A. (2004). Osteoprotegerin production by human intestinal epithelial cells: a potential regulator of mucosal immune responses. Am. J. Physiol. Gastrointest. Liver Physiol. 287: G836-G844 [Abstract] [Full Text]  
• Tay, J.Y.Y., Bay, B.H., Yeo, J.F, Harris, M., Meghji, S., Dheen, S.T. (2004). Identification of RANKL in Osteolytic Lesions of the Facial Skeleton. J. Dent. Res. 83: 349-353 [Abstract] [Full Text]  
• Lerner, U. H. (2004). NEW MOLECULES IN THE TUMOR NECROSIS FACTOR LIGAND AND RECEPTOR SUPERFAMILIES WITH IMPORTANCE FOR PHYSIOLOGICAL AND PATHOLOGICAL BONE RESORPTION. Crit. Rev. Oral Biol. Med. 15: 64-81 [Abstract] [Full Text]  
• Bharti, A. C., Takada, Y., Shishodia, S., Aggarwal, B. B. (2004). Evidence That Receptor Activator of Nuclear Factor (NF)-{kappa}B Ligand Can Suppress Cell Proliferation and Induce Apoptosis through Activation of a NF-{kappa}B-independent and TRAF6-dependent Mechanism. J. Biol. Chem. 279: 6065-6076 [Abstract] [Full Text]  
• Guillonneau, C., Louvet, C., Renaudin, K., Heslan, J.-M., Heslan, M., Tesson, L., Vignes, C., Guillot, C., Choi, Y., Turka, L. A., Cuturi, M.-C., Anegon, I., Josien, R. (2004). The Role of TNF-Related Activation-Induced Cytokine-Receptor Activating NF-{kappa}B Interaction in Acute Allograft Rejection and CD40L-Independent Chronic Allograft Rejection. J. Immunol. 172: 1619-1629 [Abstract] [Full Text]  
• Ikeda, T., Kasai, M., Suzuki, J., Kuroyama, H., Seki, S., Utsuyama, M., Hirokawa, K. (2003). Multimerization of the Receptor Activator of Nuclear Factor-{kappa}B Ligand (RANKL) Isoforms and Regulation of Osteoclastogenesis. J. Biol. Chem. 278: 47217-47222 [Abstract] [Full Text]  
• Zhang, Z., Jimi, E., Bothwell, A. L. M. (2003). Receptor Activator of NF-{kappa}B Ligand Stimulates Recruitment of SHP-1 to the Complex Containing TNFR-Associated Factor 6 That Regulates Osteoclastogenesis. J. Immunol. 171: 3620-3626 [Abstract] [Full Text]  
• McHugh, N. A., Vercesi, H. M., Egan, R. W., Hey, J. A. (2003). Receptor activator of NF-{kappa}B ligand arrests bone growth and promotes cortical bone resorption in growing rats. J. Appl. Physiol. 95: 672-676 [Abstract] [Full Text]  
• Kikuchi, T., Yoshikai, Y., Miyoshi, J., Katsuki, M., Musikacharoen, T., Mitani, A., Tanaka, S., Noguchi, T., Matsuguchi, T. (2003). Cot/Tpl2 is Essential for RANKL Induction by Lipid A in Osteoblasts. J. Dent. Res. 82: 546-550 [Abstract] [Full Text]  
• Ahuja, S. S., Zhao, S., Bellido, T., Plotkin, L. I., Jimenez, F., Bonewald, L. F. (2003). CD40 Ligand Blocks Apoptosis Induced by Tumor Necrosis Factor {alpha}, Glucocorticoids, and Etoposide in Osteoblasts and the Osteocyte-Like Cell Line Murine Long Bone Osteocyte-Y4. Endocrinology 144: 1761-1769 [Abstract] [Full Text]  
• Yonou, H., Kanomata, N., Goya, M., Kamijo, T., Yokose, T., Hasebe, T., Nagai, K., Hatano, T., Ogawa, Y., Ochiai, A. (2003). Osteoprotegerin/Osteoclastogenesis Inhibitory Factor Decreases Human Prostate Cancer Burden in Human Adult Bone Implanted into Nonobese Diabetic/Severe Combined Immunodeficient Mice. Cancer Res. 63: 2096-2102 [Abstract] [Full Text]  
• Huang, L, Cheng, Y Y, Chow, L T C, Zheng, M H, Kumta, S M (2003). Receptor activator of NF-{kappa}B ligand (RANKL) is expressed in chondroblastoma: possible involvement in osteoclastic giant cell recruitment. Mol. Pathol. 56: 116-120 [Abstract] [Full Text]  
• Sezer, O., Heider, U., Zavrski, I., Kuhne, C. A., Hofbauer, L. C. (2003). RANK ligand and osteoprotegerin in myeloma bone disease. Blood 101: 2094-2098 [Abstract] [Full Text]  
• Armstrong, A. P., Tometsko, M. E., Glaccum, M., Sutherland, C. L., Cosman, D., Dougall, W. C. (2002). A RANK/TRAF6-dependent Signal Transduction Pathway Is Essential for Osteoclast Cytoskeletal Organization and Resorptive Function. J. Biol. Chem. 277: 44347-44356 [Abstract] [Full Text]  
• Van Wesenbeeck, L., Odgren, P. R., MacKay, C. A., D'Angelo, M., Safadi, F. F., Popoff, S. N., Van Hul, W., Marks, S. C. Jr. (2002). The osteopetrotic mutation toothless (tl) is a loss-of-function frameshift mutation in the rat Csf1 gene: Evidence of a crucial role for CSF-1 in osteoclastogenesis and endochondral ossification. Proc. Natl. Acad. Sci. USA 99: 14303-14308 [Abstract] [Full Text]  
• Walton, K. J., Duncan, J. M., Deschamps, P., Shaughnessy, S. G. (2002). Heparin acts synergistically with interleukin-11 to induce STAT3 activation and in vitro osteoclast formation. Blood 100: 2530-2536 [Abstract] [Full Text]  
• Arko, B., Prezelj, J., Komel, R., Kocijancic, A., Hudler, P., Marc, J. (2002). Sequence Variations in the Osteoprotegerin Gene Promoter in Patients with Postmenopausal Osteoporosis. J. Clin. Endocrinol. Metab. 87: 4080-4084 [Abstract] [Full Text]  
• Fuller, K., Murphy, C., Kirstein, B., Fox, S. W., Chambers, T. J. (2002). TNF{alpha} Potently Activates Osteoclasts, through a Direct Action Independent of and Strongly Synergistic with RANKL. Endocrinology 143: 1108-1118 [Abstract] [Full Text]  
• Puzas, J. E., O'Keefe, R. J., Lieberman, J. R. (2002). The Orthopaedic Genome: What Does the Future Hold and Are We Ready?. JBJS 84: 133-141 [Full Text]  
• Khosla, S. (2001). Minireview: The OPG/RANKL/RANK System. Endocrinology 142: 5050-5055 [Abstract] [Full Text]  
• Lean, J. M., Fuller, K., Chambers, T. J. (2001). FLT3 ligand can substitute for macrophage colony-stimulating factor in support of osteoclast differentiation and function. Blood 98: 2707-2713 [Abstract] [Full Text]  
• Feige, U (2001). Osteoprotegerin. Ann Rheum Dis 60: iii81-84 [Full Text]  
• Pearse, R. N., Sordillo, E. M., Yaccoby, S., Wong, B. R., Liau, D. F., Colman, N., Michaeli, J., Epstein, J., Choi, Y. (2001). Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc. Natl. Acad. Sci. USA 10.1073/pnas.201394498v1 [Abstract] [Full Text]  
• FINCH, J. L., DUSSO, A. S., PAVLOPOULOS, T., SLATOPOLSKY, E. A. (2001). Relative Potencies of 1,25-(OH)2D3 and 19-Nor-1,25-(OH)2D2 on Inducing Differentiation and Markers of Bone Formation in MG-63 Cells. J. Am. Soc. Nephrol. 12: 1468-1474 [Abstract] [Full Text]  
• Lee, Z. H., Kwack, K., Kim, K. K., Lee, S. H., Kim, H.-H. (2001). Activation of c-Jun N-Terminal Kinase and Activator Protein 1 by Receptor Activator of Nuclear Factor kappa B. Mol. Pharmacol. 58: 1536-1545 [Abstract] [Full Text]  
• Chen, D., Sarikaya, N. A., Gunn, H., Martin, S. W., Young, J. D. (2001). ELISA Methodology for Detection of Modified Osteoprotegerin in Clinical Studies. Clin. Chem. 47: 747-749 [Full Text]  
• Oyajobi, B. O., Anderson, D. M., Traianedes, K., Williams, P. J., Yoneda, T., Mundy, G. R. (2001). Therapeutic Efficacy of a Soluble Receptor Activator of Nuclear Factor {{kappa}}B-IgG Fc Fusion Protein in Suppressing Bone Resorption and Hypercalcemia in a Model of Humoral Hypercalcemia of Malignancy. Cancer Res. 61: 2572-2578 [Abstract] [Full Text]  
• Yun, T. J., Tallquist, M. D., Aicher, A., Rafferty, K. L., Marshall, A. J., Moon, J. J., Ewings, M. K., Mohaupt, M., Herring, S. W., Clark, E. A. (2001). Osteoprotegerin, a Crucial Regulator of Bone Metabolism, Also Regulates B Cell Development and Function. J. Immunol. 166: 1482-1491 [Abstract] [Full Text]  
• Xing, L., Venegas, A. M., Chen, A., Garrett-Beal, L., Boyce, B. F., Varmus, H. E., Schwartzberg, P. L. (2001). Genetic evidence for a role for Src family kinases in TNF family receptor signaling and cell survival. Genes Dev. 15: 241-253 [Abstract] [Full Text]  
• Miyamoto, T., Arai, F., Ohneda, O., Takagi, K., Anderson, D. M., Suda, T. (2000). An adherent condition is required for formation of multinuclear osteoclasts in the presence of macrophage colony-stimulating factor and receptor activator of nuclear factor kappa B ligand. Blood 96: 4335-4343 [Abstract] [Full Text]  
• Gori, F., Hofbauer, L. C., Dunstan, C. R., Spelsberg, T. C., Khosla, S., Riggs, B. L. (2000). The Expression of Osteoprotegerin and RANK Ligand and the Support of Osteoclast Formation by Stromal-Osteoblast Lineage Cells Is Developmentally Regulated. Endocrinology 141: 4768-4776 [Abstract] [Full Text]  
• Fox, S. W., Fuller, K., Bayley, K. E., Lean, J. M., Chambers, T. J. (2000). TGF-{beta}1 and IFN-{gamma} Direct Macrophage Activation by TNF-{alpha} to Osteoclastic or Cytocidal Phenotype. J. Immunol. 165: 4957-4963 [Abstract] [Full Text]  
• HOLLIDAY, L. S., GLUCK, S. L., SLATOPOLSKY, E., BROWN, A. J. (2000). 1,25-Dihydroxy-19-nor-vitamin D2, a Vitamin D Analog with Reduced Bone Resorbing Activity In Vitro. J. Am. Soc. Nephrol. 11: 1857-1864 [Abstract] [Full Text]  
• Lacey, D. L., Tan, H. L., Lu, J., Kaufman, S., Van, G., Qiu, W., Rattan, A., Scully, S., Fletcher, F., Juan, T., Kelley, M., Burgess, T. L., Boyle, W. J., Polverino, A. J. (2000). Osteoprotegerin Ligand Modulates Murine Osteoclast Survival in Vitro and in Vivo. Am. J. Pathol. 157: 435-448 [Abstract] [Full Text]  
• Hofbauer, L. C., Heufelder, A. E. (2000). The Role of Receptor Activator of Nuclear Factor-{kappa}B Ligand and Osteoprotegerin in the Pathogenesis and Treatment of Metabolic Bone Diseases. J. Clin. Endocrinol. Metab. 85: 2355-2363 [Full Text]  
• Manolagas, S. C. (2000). Birth and Death of Bone Cells: Basic Regulatory Mechanisms and Implications for the Pathogenesis and Treatment of Osteoporosis. Endocr. Rev. 21: 115-137 [Abstract] [Full Text]  
• Huang, L., Xu, J., Wood, D. J., Zheng, M. H. (2000). Gene Expression of Osteoprotegerin Ligand, Osteoprotegerin, and Receptor Activator of NF-{kappa}B in Giant Cell Tumor of Bone : Possible Involvement in Tumor Cell-Induced Osteoclast-Like Cell Formation. Am. J. Pathol. 156: 761-767 [Abstract] [Full Text]  
• Capparelli, C., Kostenuik, P. J., Morony, S., Starnes, C., Weimann, B., Van, G., Scully, S., Qi, M., Lacey, D. L., Dunstan, C. R. (2000). Osteoprotegerin Prevents and Reverses Hypercalcemia in a Murine Model of Humoral Hypercalcemia of Malignancy. Cancer Res. 60: 783-787 [Abstract] [Full Text]  
• Kobayashi, K., Takahashi, N., Jimi, E., Udagawa, N., Takami, M., Kotake, S., Nakagawa, N., Kinosaki, M., Yamaguchi, K., Shima, N., Yasuda, H., Morinaga, T., Higashio, K., Martin, T. J., Suda, T. (2000). Tumor Necrosis Factor {alpha} Stimulates Osteoclast Differentiation by a Mechanism Independent of the ODF/RANKL-RANK Interaction. J. Exp. Med. 191: 275-286 [Abstract] [Full Text]  
• Fuller, K, Lean, J., Bayley, K., Wani, M., Chambers, T. (2000). A role for TGFbeta(1) in osteoclast differentiation and survival. J. Cell Sci. 113: 2445-2453 [Abstract]  
• Itonaga, I, Sabokbar, A, Murray, D W, Athanasou, N A (2000). Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages. Ann Rheum Dis 59: 26-31 [Abstract] [Full Text]  
• Arai, F., Miyamoto, T., Ohneda, O., Inada, T., Sudo, T., Brasel, K., Miyata, T., Anderson, D. M., Suda, T. (1999). Commitment and Differentiation of Osteoclast Precursor Cells by the Sequential Expression of c-Fms and Receptor Activator of Nuclear Factor {kappa}B (RANK) Receptors. J. Exp. Med. 190: 1741-1754 [Abstract] [Full Text]  
• Hjertner, O., Torgersen, M. L., Seidel, C., Hjorth-Hansen, H., Waage, A., Borset, M., Sundan, A. (1999). Hepatocyte Growth Factor (HGF) Induces Interleukin-11 Secretion From Osteoblasts: A Possible Role for HGF in Myeloma-Associated Osteolytic Bone Disease. Blood 94: 3883-3888 [Abstract] [Full Text]  
• Thomas, R. J., Guise, T. A., Yin, J. J., Elliott, J., Horwood, N. J., Martin, T. J., Gillespie, M. T. (1999). Breast Cancer Cells Interact with Osteoblasts to Support Osteoclast Formation. Endocrinology 140: 4451-4458 [Abstract] [Full Text]  
• Lee, S.-K., Lorenzo, J. A. (1999). Parathyroid Hormone Stimulates TRANCE and Inhibits Osteoprotegerin Messenger Ribonucleic Acid Expression in Murine Bone Marrow Cultures: Correlation with Osteoclast-Like Cell Formation. Endocrinology 140: 3552-3561 [Abstract] [Full Text]  
• Jimi, E., Akiyama, S., Tsurukai, T., Okahashi, N., Kobayashi, K., Udagawa, N., Nishihara, T., Takahashi, N., Suda, T. (1999). Osteoclast Differentiation Factor Acts as a Multifunctional Regulator in Murine Osteoclast Differentiation and Function. J. Immunol. 163: 434-442 [Abstract] [Full Text]  
• Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M. T., Martin, T. J. (1999). Modulation of Osteoclast Differentiation and Function by the New Members of the Tumor Necrosis Factor Receptor and Ligand Families. Endocr. Rev. 20: 345-357 [Abstract] [Full Text]  
• Burgess, T. L., Qian, Y.-x., Kaufman, S., Ring, B. D., Van, G., Capparelli, C., Kelley, M., Hsu, H., Boyle, W. J., Dunstan, C. R., Hu, S., Lacey, D. L. (1999). The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts. J. Cell Biol. 145: 527-538 [Abstract] [Full Text]  
• Lomaga, M. A., Yeh, W.-C., Sarosi, I., Duncan, G. S., Furlonger, C., Ho, A., Morony, S., Capparelli, C., Van, G., Kaufman, S., van der Heiden, A., Itie, A., Wakeham, A., Khoo, W., Sasaki, T., Cao, Z., Penninger, J. M., Paige, C. J., Lacey, D. L., Dunstan, C. R., Boyle, W. J., Goeddel, D. V., Mak, T. W. (1999). TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 13: 1015-1024 [Abstract] [Full Text]  
• Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H.-L., Elliott, G., Kelley, M. J., Sarosi, I., Wang, L., Xia, X.-Z., Elliott, R., Chiu, L., Black, T., Scully, S., Capparelli, C., Morony, S., Shimamoto, G., Bass, M. B., Boyle, W. J. (1999). Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. USA 96: 3540-3545 [Abstract] [Full Text]  
• Collin-Osdoby, P., Rothe, L., Anderson, F., Nelson, M., Maloney, W., Osdoby, P. (2001). Receptor Activator of NF-kappa B and Osteoprotegerin Expression by Human Microvascular Endothelial Cells, Regulation by Inflammatory Cytokines, and Role in Human Osteoclastogenesis. J. Biol. Chem. 276: 20659-20672 [Abstract] [Full Text]  
• Zhou, H., Kartsogiannis, V., Hu, Y. S., Elliott, J., Quinn, J. M. W., McKinstry, W. J., Gillespie, M. T., Ng, K. W. (2001). A Novel Osteoblast-derived C-type Lectin That Inhibits Osteoclast Formation. J. Biol. Chem. 276: 14916-14923 [Abstract] [Full Text]  
• Pearse, R. N., Sordillo, E. M., Yaccoby, S., Wong, B. R., Liau, D. F., Colman, N., Michaeli, J., Epstein, J., Choi, Y. (2001). Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc. Natl. Acad. Sci. USA 98: 11581-11586 [Abstract] [Full Text]  

Home | Help | Feedback | Subscriptions | Archive | Search

TABLE OF CONTENTS